Lercanidipine
As of the edition of 20 October 2026, Lercanidipine is a small molecule: marketed, first approved in 1998 (ES); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Zanidip
- First approved
- 1 June 1998 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Recordati; 3 holders in all
- Registered trials
- 9, 1 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 1 | 2 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Recordati | Applicant and Lead sponsor of trials | 2004 to now |